A search for active bacterial growth inhibitors among seven highly potent morphine-like narcotics revealed that NIH 7591 and etorphine inhibited the rates of growth of Escherichia coli by 50% at 1.9 x 10-4 M. Bacterial cultures escaped from growth inhibition by NIH 7591 after times which were proportional to the drug concentrations and inversely proportional to the initial bacterial densities. Populations of E. coli could adapt to resist and cross-resist growth inhibitions by NIH 7591 and phenazocine. Resistance was lost after growth in drug-free medium for a few doubling times. The agonist-antagonist pair, etorphine and diprenorphine, inhibited growth of E. coli additively without any indication of antagonism. Actions of narcotics in bacteria is considered a theme in its own right.
With the expectation of gaining insight into biochemical capacities of morphine-like narcotics, effects of such substances have been studied in bacteria over the past decade with the following results. Certain synthetic narcotics inhibit bacterial growth (21) . This is accompanied by reduced ribonucleic acid (24) , protein (10, 24) and deoxyribonucleic acid (10) biosyntheses, alterations in lipid metabolism and composition (27) , changes in the transport of certain amino acids (12) , polyamines (22) and Mg2+ (7) across membranes, mobilization of (probably membrane associated) adenosine triphosphatase (10) , and other interferences with bacterial envelope functions such as the adsorption of bacteriophage (19) or the formation of mating pairs (14) . A bactericidal effect of levallorphan at 3.8 x 10-3 M has also been attributed to an action on the bacterial membrane (3) . The nonoccurrence of ribonucleic acid biosynthesis in Escherichia coli, exposed to levallorphan, has been studied especially with respect to attending features of biochemical regulation (4, 5, 11) .
However, there has remained a question if such physiological and biochemical studies of effects of morphine-like narcotics merely represent a theme in bacteriology or also have relevance to the actions of these narcotics in mammals. In view of this conceptual impasse, we have not attempted to make further additions to the inventory of biochemical and physiological actions of narcotics in bacteria, nor to explain known effects in molecular terms.
Instead, we asked the question if bacterial cultures can satisfy criteria of meaningful model systems for the study of actions of narcotics as they relate to mammalian neuropharmacology. Among such criteria are: (i) the occurrence of significant effects at narcotic concentrations lower than nonspecific toxic levels of many chemicals, i.e., ca. 10-3 M; (ii) the ability to develop tolerance and cross-tolerance to narcotics; and (iii) the manifestation of an interplay between narcotic agonists and antagonists. We have tested for these occurrences in cultures of E. coli and report that: (i) bacterial growth rates were reduced 50% by NIH 7591 and etorphine at 1.9 x 10-4 M; (ii) E. coli B populations became resistant and cross-resistant to NIH 7591 and phenazocine within a few doubling times (of drug-free control cultures); and (iii) etorphine and diprenorphine inhibited growth of .E. coli W additively without indications of an antagonism between these two compounds. 2 ). Culture vessels were incubated at 37 C with mechanical agitation. and bacterial densities were measured either in a spectrophotometer (Beckman DU) or in a colorimeter (Bausch & Lomb Spectronic 20) (when bacterial cultures were grown in test tube cuvettes). Incorporation of radioactive compounds into bacteria was determined as described proviously (27) . Isobolograms for the combined actions of etorphine and diprenorphine on growth of E. coli W were constructed as described (8, 13) .
MATERIALS AND METHODS

RESULTS
Inhibition of bacterial growth by NIH 7591. Morphine, dissolved to saturation in liquid medium, has no effect on the growth of E. coli (21) . The earliest report of inhibitions of growth of E. coli by synthetic narcotics mentioned a parallelism between the antibacterial potencies of several compounds and their toxicity for mammals (21) . Therefore, in our search for more active growth inhibitors, we selected six highly potent experimental narcotics from a tabulation of such substances (16) and screened them for their effects on growth of E. coli B in liquid medium (Fig. 1) . The most active compound was NIH 7591 (Fig. 2 ) which, at 10-3 M, inhibited bacterial growth completely. Figure 3 shows the influence of graded concentrations of NIH 7591 on the growth of E. coli B. At 6 x 10-4 M, complete inhibition was maintained for approximately three doubling times of a drug-free control culture. At 10-5 M, the drug had no effect. Expressing the decreases of growth rates during the first 60 min as the percentage of inhibition and plotting these percentages as a function of the logarithm of concentration of NIH 7591 yielded a typical log dosage-response correlation (data not shown) from which the 50% inhibitory concentration of the drug was interpolated to be 1.9 x 10-4 M. The standard log dosage-response curve is indicative of a quantified response that results from a reversible occupancy of drug receptors by the law of mass action (20) .
Growth inhibition by NIH 7591 was an inverse function of the bacterial density at the time of addition of the drug. Three cultures of E. coli B whose densities differed by ratios of approximately 1:2:3 were tested for their response to 4 x 1Q-4 M NIH 7591 (Fig. 4 ). The culture with the lowest density was inhibited for VOL. 7, 1975 (20) .
Escape of E. coli B from growth inhibition by NIH 7591. Growth resumed in cultures of E. coli B after periods of time which were functions of the concentration of NIH 7591 (Fig. 3) or inverse functions of the initial bacterial densities (Fig. 4) . A slow recovery from growth inhibition was also observed on drug-free culture plates which had been seeded with NIH 7591-treated bacteria to determine the influence of the drug on the viability of the test organism. E. coli B liquid cultures were supplied with 6 x 10-4 M drug, and portions were taken at that time and at hourly intervals thereafter for 4 h. These portions were diluted and plated, and the numbers of colonies were counted after 24 and 48 h of incubation (Fig. 5) . Cells of the drug-exposed culture produced, in the first 24 h, colonies in numbers which suggested a decline in viable organisms by 95% after 3 h of exposure to NIH 7591; plate counts after 4 h of exposure indicated that escape from growth inhibition had begun. When these plates were recounted after a second 24-h incubation, they showed an identical number of colonies for all portions taken, corresponding to a bacterial titer of 2.4 x 107 organisms per ml, i.e., identical to the initial bacterial density. NIH 7591, at 6 x 10-4 M, hence, was bacteriostatic, but individual cells of E. coli required different periods of time to recover from exposure to the drug.
In different recovery experiments, others have observed that E. coli, resuspended in drug-free medium after 11 min of exposure to 5 x 10-3 M levallorphan, resumed protein biosynthesis immediately at the rate of an untreated control culture, whereas ribonucleic acid synthesis required -10 min to attain the control rate (10) . On the other hand, changes in lipid composition of E. coli which had been induced during exposure to 1.35 x 10-3 M levorphanol for 70 min reverted only slowly to normality after the bacteria were resuspended in drug-free medium (28) . (Fig. 3) were collected by centrifugation and suspended in fresh media containing either 4 x 10-4 or 8 x 10-4 M drug. Pre-exposed bacteria resumed growth immediately in medium containing 4 x 10-4 M NIH 7591 and also grew, after a lag, exponentially in the presence of 8 x 10-4 M drug, whereas bacteria from a drug-free control culture remained inhibited. Hence, the ability to resist growth inhibition by NIH 7591 was a property which the bacterial cells had acquired during a first exposure and continued to exhibit upon second exposure to the same or to a higher concentration of the drug which was bacteriostatic for organisms that were not adapted.
Adaptation of E. coli B was not restricted to NIH 7591. Bacterial populations which had resumed growth after initial inhibitions by 7.2 x 10-4 M NIH 7591 or 2.5 x 10-3 M phenazocine (Fig. 2b) were harvested, resuspended in fresh media without drugs or containing either 8 x 10-4 M NIH 7591 or 2.8 x 10-3 M phenazocine, and incubated. Bacteria which had grown in drug-free medium were processed in the same manner. All bacteria grew immediately with identical rates in drug-free medium (Fig. 6) ; bacteria which had been pre-exposed to NIH 7591 grew immediately in the presence of either this drug or of phenazocine, and bacteria which had been pre-exposed to phenazocine grew immediately in the presence of either this drug or of NIH 7591. Bacteria which had not been pre-exposed to drugs were inhibited by either drug (Fig. 6) .
The adaptation phenomenon involved entire test populations and, hence, was not the result of a selective propagation of random mutants (to resistance) under drug pressure. Even assuming an improbably high mutation rate of 1 per 104 cells per doubling time, at least 12 doublings, i.e., approximately 10 h of incubation, would have been required before the growth of resistant mutants would have become turbidimetrically detectable. Furthermore, when resistant populations of E. coli B were grown for a few doubling times in the absence of the drugs, these cultures regained sensitivity.
Influence of NIH 7591 on macromolecular biosyntheses in E. coli B. Growth inhibitions of E. coli by levorphanol (1.8 x 10-3 M) or levallorphan (5 x 10-3 M) are attended by failures of ribonucleic acid (24) or deoxyribonucleic acid (10) biosyntheses. We tested for analogous effects of NIH 7591 and found that at 8 x 10-4 M of the drug, incorporations of [14CJuracil and [3H]thymidine into E. coli B failed entirely. We shall report elsewhere that treatment of these bacteria with toluene rendered both categories of nucleic acid biosynthesis insensitive to 1.5 x 10-3M NIH 7591. At 4 x 10-4 M drug, nucleic acid biosyntheses did not occur in E. coli B during the first 90 min of exposure to NIH 7591, after which these syntheses resumed, inasmuch as the bacterial populations resumed growth. (right) after the bacteria had escaped from growth inhibition by either 2.5 x 10-3M phenazocine (x) or 7.2 x 10-4 M NIH 7591 (0). The growth of control bacteria which had not been pre-exposed to drugs was inhibited (0); pre-exposed and control bacteria grew at identical rates in drug-free medium (left). Calibration of the ordinate is as in Fig. 4 (Fig. 7) . The incorporation of radioleucine into proteins of E. coli has been reported to be decreased 50% in the presence of 1.8 x 10-3 M levorphanol, whereas ribonucleic acid biosynthesis was decreased 85 to 90% (24) . The differential effect of NIH 7591 on ribonucleic acid and protein synthesis in E. coli B, hence, was more pronounced. We discuss below the possible implication of continued protein biosynthesis for the adaptation of E. coli B to NIH 7591.
Additive growth inhibition of E. coli W by etorphine and diprenorphine. The agonistantagonist pair, etorphine and diprenorphine (Fig. 8) , was selected for an attempt to demonstrate an antagonistic interplay of effects on growth of E. coli for the following reasons. Etorphine is a highly potent narcotic analgesic which is approximately 3,000 times as active as morphine (1) . Its antagonist, diprenorphine, is a "pure" antagonist in that it exhibits no agonistic properties of its own, unlike levallorphan, nalorphine, and pentazocine. In fact, it reverses the analgesic activities of these "antagonists- analgesics" (2) . The lactate-mineral salts medium at pH 8.2 was chosen because it is optimal for the demonstration of growth inhibitions by synthetic narcotics (21) .
Exponential growth rates of drug-free control cultures of E. coli W and of cultures containing either graded concentrations of etorphine or diprenorphine. or graded concentrations of combined drugs in a factorial experimental design were determined turbidimetrically, and 50% rate-inhibiting concentrations of the single drugs or of drug combinations were interpolated from these results. They are listed in Table 1 Table 1 as fractional inhibitory concentrations. The last column of Table 1 shows that the sums of fractional-inhibitory concentrations for each drug pair, representing jointly one mean effective dose, were close to unity. Hence, growth inhibitions by etorphine and diprenorphine were additive. When the two sets of fractional inhibitory concentrations were plotted as a function of each other, the isobologram (Fig. 9 ) was obtained, which is indicative of an additive action (8, 13) . Had diprenorphine antagonized the growth inhibition by etorphine, the isobologram would have curved out in the direction of the upper right quadrant of the coordinate system. DISCUSSION Searching among highly potent morphinelike analgesics for superior inhibitors of bacterial growth, we found that NIH 7591, which is -30 times as analgesic as morphine (16), and etorphine, which is -100 times more active than NIH 7591, exceeded the growth inhibitory activity of levorphanol for E. coli by not more than factors of 2 or 3. NIH 7564 resembled levorphanol in its growth-inhibitory activity for E. coli, whereas NIH 7630, 7579, 7665, and 7606 permitted logarithmic growth of the test organism at rates which were only slightly less than that of a drug-free control culture (Fig. 1) .
Analgesic concentrations of morphine in human plasma have been estimated to be 10-6 M (25) , and a representative concentration of 1 (17) . The same quantity, in 1 ml of water, would amount to 6 x 10-7 M. By comparison, 10-5 M NIH 7591 or etorphine had no effect on the growth of E. coli. Whereas the possibility cannot be excluded that among the many experimental morphine-like narcotics there may be compounds with higher antibacterial activities, our current search among potent analgesics has not turned up such substances; evidently analgesic and antibacterial potencies are not correlated.
The additive growth-inhibitory effects of etorphine and diprenorphine show the absence of an antagonistic interplay of these two compounds in E. coli. Additive effects point to either additive occupancy of the same drug receptor or separate blockades of two concurrent metabolic pathways which both contribute to the parameter whose inhibition is measured. The only instance of narcotic antagonism in microorganisms has been reported for Amoeba proteus, in which morphine stabilized the pseudopods to hydrostatic pressure, whereas subsequent exposure to nalorphine reversed this effect (29) . To our knowledge, the literature does not record any experiments in which microorganisms have been exposed to an agonist and antagonist simultaneously. Competition between the antagonists-analgesics. levallorphal and naloxone, concerning binding to an isolated drug receptor from mouse brain has recently been reported (15) ; furthermore, this binding reaction is stereospecific (15) . This contrasts to the lack of stereospecificity of the growth-inhibitory effect of levorphanol on E. coli, in which its enantiomer, dextrorphan, is only 20 to 30% less effective than the drug itself (21) . It follows that E. coli does not possess structural and functional equivalents of mammalian central nervous system (CNS) receptors of morphine-like drugs. The adaptation of populations of E. coli to become resistant and cross-resistant to NIH 7591 and phenazocine is reminiscent of the development of tolerance and cross-tolerance to narcotics in the mammalian organism. Since resumed replication of bacteria is a parameter quite different from the hypothetical tolerance producing events in the mammalian CNS, which does possess highly specific receptors and whose component cells do not replicate, our observations on bacterial adaptation to narcotics may signify no more than a coincidental similarity.
Phenotypic adaptations of bacterial populations to resist growth-inhibitory drugs have been observed in E. coli (18) , Staphylococcus aureus (26) , and Bacillus cereus (6) . In these VOL. 7, 1975 on September 12, 2017 by guest http://aac.asm.org/ three instances there exists direct or circumstantial evidence that adaptations involved protein biosynthesis. We note that protein synthesis, measured by incorporation of [I4C ]-phenylalanine, continued in E. coli B, whose growth was inhibited by NIH 7591 (Fig. 7) .
We conclude that bacteriological studies on morphine-like drugs are an independent research topic. Whether biochemical and physiological results of such studies are relevant to the mode of action of such narcotics in the mammalian CNS cannot be decided until these actions are known in greater detail.
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